¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ÆÐÇ÷ÁõÀº °¨¿°À¸·Î ÀÎÇÑ »ý¸íÀ» À§ÇùÇÏ´Â ÇÕº´ÁõÀ¸·Î, °¨¿°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀÀÌ ÀÚ½ÅÀÇ Á¶Á÷°ú Àå±â¸¦ ¼Õ»ó½ÃÅ´À¸·Î½á ¹ß»ýÇÕ´Ï´Ù. ÆÐÇ÷ÁõÀº ´Ù¹ß¼º Àå±âºÎÀü ¹× »ç¸ÁÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ Á¶±â¿¡ ¹ß°ßÇÏ°í ½Å¼ÓÇÏ°Ô Ä¡·áÇÏÁö ¾ÊÀ¸¸é »ç¸Á¿¡ ´ÞÇÒ ¼ö ÀÖ´Ù(Elfeky et al., 2017)(Rudd et al., 2020). ÆÐÇ÷ÁõÀº ´©±¸¿¡°Ô³ª ¹ßº´ÇÒ ¼ö ÀÖÁö¸¸, 1¼¼ ¹Ì¸¸ÀÇ ¾î¸°ÀÌ, ³ëÀÎ, ¸é¿ªÃ¼°è°¡ ¾àÇÑ »ç¶÷¿¡°Ô¼ ´õ ÈçÇÏ°Ô ³ªÅ¸³´Ù(Elfeky et al., 2017). ¸ðµç °¨¿°(¼¼±Õ, ¹ÙÀÌ·¯½º, Áø±Õ)ÀÌ ÆÐÇ÷ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖÁö¸¸, Æó·Å, º¹ºÎ °¨¿°, ½ÅÀå °¨¿°, Ç÷·ù °¨¿°(±ÕÇ÷Áõ)À» ¾Î°í ÀÖ´Â »ç¶÷Àº ÆÐÇ÷Áõ¿¡ °É¸®±â ½±½À´Ï´Ù. ÆÐÇ÷ÁõÀÇ °¡Àå ÈçÇÑ º´¿øÃ¼·Î´Â ¼¼±Õ(±×¶÷ ¾ç¼º, ±×¶÷ À½¼º), °õÆÎÀÌ µîÀÌ ÀÖ½À´Ï´Ù(Quenot et al., 2013).
ÆÐÇ÷Áõ°ú ÆÐÇ÷Áõ¼º ¼îÅ©´Â »ý¸íÀ» À§ÇùÇÏ´Â ÁúȯÀ¸·Î »ç¸Á·üÀÌ ¸Å¿ì ³ô½À´Ï´Ù(Shankar-Hari et al., 2017)(Dupuis et al., 2020). ÆÐÇ÷ÁõÀº °¨¿°¿¡ ´ëÇÑ ¼÷ÁÖÀÇ ºñÁ¤»óÀûÀÎ ¹ÝÀÀÀ¸·Î ÀÎÇÑ »ý¸íÀ» À§ÇùÇÏ´Â Àå±â ±â´É Àå¾Ö·Î Á¤Àǵ˴ϴÙ(Singer et al., 2016)(Shankar-Hari et al., 2017). ÆÐÇ÷Áõ¼º ¼îÅ©´Â Áö¼ÓÀûÀÎ µ¿¸Æ¼º ÀúÇ÷¾ÐÀ» Ư¡À¸·Î ÇÏ´Â ±Þ¼º ¼øÈ¯ ºÎÀü »óÅÂÀ̸ç, ¼ö¾× ¼Ò»ý¼ú·Î »ý¸íÀ» ±¸ÇÒ ¼ö ¾ø´Â »óÅ·ΠÁ¤Àǵ˴ϴÙ(Singer et al., 2016)(Shankar-Hari et al., 2017). ÆÐÇ÷Áõ°ú ÆÐÇ÷Áõ¼º ¼îÅ©ÀÇ Áø´Ü¿¡´Â ÀÓ»ó µ¥ÀÌÅÍ, °Ë»ç µ¥ÀÌÅÍ, »ý¸®Àû µ¥ÀÌÅÍ, ¹Ì»ý¹°ÇÐÀû µ¥ÀÌÅÍÀÇ Á¶ÇÕÀÌ ÇÊ¿äÇÕ´Ï´Ù(Singer et al., 2016).
ÁÖ¿ä 8 ½ÃÀå(¹Ì±¹, ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹, ÀϺ», Áß±¹)ÀÇ ÆÐÇ÷Áõ¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ÆÐÇ÷Áõ ¹× ÆÐÇ÷Áõ¼º ¼îÅ©ÀÇ ¸®½ºÅ© ¿äÀÎ ¹× °ú°Å ¿ªÇÐÀÇ µ¿Çâ¿¡ °üÇÑ Á¤º¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¸ñÂ÷
Á¦2Àå GlobalData ¼Ò°³
Á¦3Àå ÆÐÇ÷Áõ : °³¿ä
- Ã˸Å
- °ü·Ã ¸®Æ÷Æ®
- ÇâÈÄ ¸®Æ÷Æ®
Á¦4Àå ¿ªÇÐ
- ÁúȯÀÇ ¹è°æ
- À§Çè ÀÎÀÚ¿Í º´Á¸ Áúȯ
- ¼¼°èÀÇ °ú°Å µ¿Çâ
- ÁÖ¿ä 8 ½ÃÀåÀÇ ¿¹Ãø ¹æ¹ý
- ÆÐÇ÷Áõ°ú ÆÐÇ÷Áõ¼º ¼îÅ©ÀÇ ¿ªÇÐÀû ¿¹Ãø(2023-2033³â)
- ÆÐÇ÷ÁõÀ¸·Î Áø´ÜµÈ ȯÀÚ
- ÆÐÇ÷ÁõÀ¸·Î Áø´ÜµÈ ȯÀÚ : ¿¬·Éº°
- ÆÐÇ÷ÁõÀ¸·Î Áø´ÜµÈ ȯÀÚ : ¼ºº°
- ÆÐÇ÷ÁõÀ¸·Î Áø´ÜµÈ ȯÀÚ : º´¿øÃ¼º°
- ÆÐÇ÷ÁõÀ¸·Î Áø´ÜµÈ ȯÀÚÀÇ Àå±â ±â´É Àå¾Ö
- ÆÐÇ÷Áõ¿¡ ÀÇÇÑ ¿ø³» »ç¸Á ¿¹
- ÆÐÇ÷Áõ¼º ¼îÅ©·Î Áø´ÜµÈ ȯÀÚ
- ÆÐÇ÷Áõ¼º ¼îÅ©·Î Áø´ÜµÈ ȯÀÚ : ¿¬·Éº°
- ÆÐÇ÷Áõ¼º ¼îÅ©·Î Áø´ÜµÈ ȯÀÚ : ¼ºº°
- ÆÐÇ÷Áõ¼º ¼îÅ©·Î Áø´ÜµÈ ȯÀÚ : º´¿øÃ¼º°
- ÆÐÇ÷Áõ¼º ¼îÅ©·Î Áø´ÜµÈ ȯÀÚÀÇ Àå±â ±â´É Àå¾Ö
- ÆÐÇ÷Áõ¼º ¼îÅ©¿¡ ÀÇÇÑ ¿ø³» »ç¸Á ¿¹
- ÀλçÀÌÆ®
- ¿ªÇÐÀû ¿¹Ãø ÀλçÀÌÆ®
- COVID-19ÀÇ ¿µÇâ
- ºÐ¼®ÀÇ ÇѰè
- ºÐ¼® °Á¡
Á¦5Àå ºÎ·Ï
Á¦6Àå ¹®ÀÇ
KSA 24.10.31
Sepsis is a life-threatening complication arising from an infection, which occurs when the body's response to the infection damages its own tissues and organs. Sepsis causes multiple organ failure and death, especially if it is not recognized early and treated promptly (Elfeky et al., 2017; Rudd et al., 2020). Anyone can develop sepsis, but the condition is more common in children younger than one year of age, older adults, and those with weakened immune systems (Elfeky et al., 2017). Although any type of infection (bacterial, viral, or fungal) can lead to sepsis, people suffering from pneumonia, abdominal infection, kidney infection, and bloodstream infection (bacteremia) are more likely to develop sepsis. The most common pathogens for sepsis include bacteria (Gram-positive, Gram-negative), and fungi (Quenot et al., 2013).
Sepsis and septic shock are life-threatening conditions with an extremely high mortality rate (Shankar-Hari et al., 2017; Dupuis et al., 2020). Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al., 2016; Shankar-Hari et al., 2017). Septic shock is defined as a state of acute circulatory failure characterized by persistent arterial hypotension that cannot be successfully rescued by fluid resuscitation (Singer et al., 2016; Shankar-Hari et al., 2017). A constellation of clinical, laboratory, physiologic, and microbiologic data is needed for the diagnosis of sepsis and septic shock (Singer et al., 2016).
Scope
- This report provides an overview of the risk factors and the global and historical epidemiological trends for sepsis and septic shock in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
- Additionally, this report includes a 10-year epidemiological forecast of sepsis for men and women from 2023-33 for the following segmentations in all ages across the 8MM: diagnosed incident cases of sepsis segmented by sex and age (ages 0-28 days, 1 month-17 years, 18-64 years, and 65 years and older), diagnosed incident cases of sepsis by causative agent (Gram positive and Gram negative bacteria, fungi, and other organism), diagnosed incident cases of sepsis by organ dysfunction (acute kidney dysfunction, acute respiratory dysfunction, disseminated intravascular coagulopathy [DIC], hepatic dysfunction, and cardiovascular dysfunction), and in-hospital mortality of sepsis.
- This report also includes a 10-year epidemiological forecast of septic shock for men and women from 2023-33 for the following segmentations in all ages across the 8MM: diagnosed incident cases of septic shock segmented by sex and age (0-28 days, 1 month-17 years, 18-64 years, and 65 years and older), diagnosed incident cases of septic shock by causative agent, agent (gram positive and gram negative bacteria, fungi, and other organism) diagnosed incident cases of septic shock by organ dysfunction (acute kidney dysfunction, acute respiratory dysfunction, DIC, hepatic dysfunction, and cardiovascular dysfunction), and in-hospital mortality of septic shock.
Reasons to Buy
- Sepsis Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global sepsis markets.
- Quantify patient populations in the global sepsis markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for sepsis therapeutics in each of the markets covered.
- Understand magnitude of the sepsis population by age, sex, causative agent, and organ dysfunction.
Table of Contents
1. List of Contents
- 1.1. List of Tables
- 1.2. List of Figures
2. About GlobalData
3. Sepsis: Executive Summary
- 3.1. Catalyst
- 3.2. Related reports
- 3.3. Upcoming reports
4. Epidemiology
- 4.1. Disease background
- 4.2. Risk factors and comorbidities.
- 4.3. Global and historical trends
- 4.4. 8MM forecast methodology.
- 4.4.1. Sources
- 4.4.2. Forecast assumptions and methods.
- 4.4.3. Forecast assumptions and methods: diagnosed incident cases of sepsis
- 4.4.4. Forecast assumptions and methods: diagnosed incident cases of sepsis by causative agent.
- 4.4.5. Forecast assumptions and methods: organ dysfunction in diagnosed incident cases of sepsis.
- 4.4.6. Forecast assumptions and methods: sepsis in-hospital mortality cases.
- 4.4.7. Forecast assumptions and methods: diagnosed incident cases of septic shock.
- 4.4.8. Forecast assumptions and methods: diagnosed incident cases of septic shock by causative agent.
- 4.4.9. Forecast assumption and methods: organ dysfunction in diagnosed incident cases of septic shock.
- 4.4.10. Forecast assumption and methods: septic shock in-hospital mortality cases.
- 4.5. Epidemiological forecast for sepsis and septic shock (2023–33)
- 4.5.1. Diagnosed incident cases of sepsis.
- 4.5.2. Age-specific diagnosed incident cases of sepsis
- 4.5.3. Sex-specific diagnosed incident cases of sepsis
- 4.5.4. Diagnosed incident cases of sepsis by causative agent.
- 4.5.5. Organ dysfunction in diagnosed incident cases of sepsis
- 4.5.6. Sepsis in-hospital mortality cases
- 4.5.7. Diagnosed incident cases of septic shock.
- 4.5.8. Age-specific diagnosed incident cases of septic shock
- 4.5.9. Sex-specific diagnosed incident cases of septic shock
- 4.5.10. Diagnosed incident cases of septic shock by causative agent
- 4.5.11. Organ dysfunction in diagnosed incident cases of septic shock
- 4.5.12. Septic shock in-hospital mortality cases
- 4.6. Discussion
- 4.6.1. Epidemiological forecast insight
- 4.6.2. COVID-19 impact.
- 4.6.3. Limitations of the analysis
- 4.6.4. Strengths of the analysis
5. Appendix
- 5.1. Bibliography
- 5.2. About the Authors
- 5.2.1. Epidemiologist
- 5.2.2. Reviewers
- 5.2.3. Vice President of Disease Intelligence and Epidemiology
- 5.2.4. Global Head of Pharma Research, Analysis and Competitive Intelligence
6. Contact Us